The bare lymphocyte syndrome.

Abstract:

:The bare lymphocyte syndrome is a combined immunodeficiency resulting from the lack of expression of either class I or class II HLA antigens at the cell surface. The main clinical manifestations are infections of the respiratory or the digestive tract. The immunodeficiency involves the absence of antibody formation and the absence of cell-mediated response, to specific antigen, contrasting with virtually normal transplant immunity to allogeneic determinants. The responsible gene(s) is not born by chromosome 6. The best treatment appears, at the present time, to be in utero stem cell transplantation into the sick fetus, and it may, in the future, be gene therapy.

journal_name

Bone Marrow Transplant

authors

Touraine JL,Marseglia GL,Betuel H,Souillet G,Gebuhrer L

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

54-6

eissn

0268-3369

issn

1476-5365

journal_volume

9 Suppl 1

pub_type

杂志文章,评审
  • Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin.

    abstract::Respiratory syncytial virus (RSV), a common cause of both upper and lower respiratory tract infection (LRTI) in infants and children, is rarely described as an infective agent in adults. It has been reported in bone marrow transplant (BMT) recipients and patients with malignancy immunosuppressed by chemotherapy. Such ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701091

    authors: McColl MD,Corser RB,Bremner J,Chopra R

    更新日期:1998-02-01 00:00:00

  • Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study.

    abstract::We conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. The median time for neutrophil engraftment was 13 days (11-20 days), and for platelets was 15 days (11...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.154

    authors: Chen J,Wang RX,Chen F,Sun AN,Qiu HY,Jin ZM,Tang XW,Han Y,Fu ZZ,He GS,Miao M,Ma X,Wu DP

    更新日期:2014-02-01 00:00:00

  • Oral ciprofloxacin as antibacterial prophylaxis after allogeneic bone marrow transplantation: a reappraisal.

    abstract::The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702043

    authors: Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

    更新日期:1999-12-01 00:00:00

  • T cell tolerance after bone marrow transplantation in mice.

    abstract::This article provides a brief overview of T cell tolerance induction in the thymus, using parent----F1 bone marrow (BM) chimeras as a model. Although intrathymic tolerance is controlled largely by BM-derived cells, experiments with BM chimeras suggest that thymic epithelial cells can make a major contribution to toler...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Sprent J,Kosaka H,Gao EK

    更新日期:1992-01-01 00:00:00

  • Mesenchymal stem cells: heading into the clinic.

    abstract::In recent years, there has been an increasing interest in non-hematopoietic pluripotent progenitor cells that are found in the bone marrow. Mesenchymal stem cells (MSCs) are the first non-hematopoietic progenitors to be isolated from the bone marrow and extensively characterized. In addition to their ability to suppor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1702791

    authors: Koç ON,Lazarus HM

    更新日期:2001-02-01 00:00:00

  • Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.

    abstract::The aim of this phase II study was to determine the feasibility of using two (tandem) courses of high-dose alkylating agents with bone marrow or peripheral blood progenitor cell support in women with stage IV breast cancer. Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Bitran JD,Samuels B,Klein L,Hanauer S,Johnson L,Martinec J,Harris E,Kempler J,White W

    更新日期:1996-02-01 00:00:00

  • Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis.

    abstract::Microangiopathic hemolytic anemia (MAHA) is a well-described complication of stem cell transplantation. Plasmapheresis is one modality utilized as therapy for patients who develop this complication. However, plasmapheresis may alter whole blood levels of certain medications and its effect on tacrolimus in bone marrow ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702174

    authors: Hale GA,Reece DE,Munn RK,Kniska AB,Phillips GL

    更新日期:2000-02-01 00:00:00

  • A risk-adapted approach to acute GVHD treatment: are we there yet?

    abstract::Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials ha...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.261

    authors: Holtan SG,MacMillan ML

    更新日期:2016-02-01 00:00:00

  • Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.

    abstract::We assessed mammaglobin (MMG) gene expression in bone marrow (BM) aspirates from patients with advanced breast cancer who had received a reduced-intensity conditioning and stem cell allografting, in order to detect a graft-versus-tumor effect on micrometastatic disease. Nine patients received a reduced-intensity condi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705248

    authors: Bregni M,Fleischhauer K,Bernardi M,Pescarollo A,Guggiari E,Lunghi F,Deola S,Scaramuzza S,Re F,Setola E,Monari M,Mazzi B,Servida P,Corradini P,Peccatori J

    更新日期:2006-02-01 00:00:00

  • Hemopoietic stem cell processing: comparison of progenitor cell recovery using the Cobe 2991 cell washer and the Haemonetics V50 apheresis system.

    abstract::Using 24 bone marrow (BM) harvests intended for cryopreservation and transplantation, we compared the use of the Cobe 2991 cell washer (2991) and the Haemonetics V50 apheresis system (HV50) for automated BM processing. Our in vitro data indicate that while the mononuclear cell (MNC) concentration of the HV50 product w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Preti RA,Ahmed T,Ayello J,Helson L,Argani I,Wuest D,Ciavarella D

    更新日期:1992-05-01 00:00:00

  • The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.

    abstract::In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705846

    authors: Nasilowska-Adamska B,Rzepecki P,Manko J,Czyz A,Markiewicz M,Federowicz I,Tomaszewska A,Piatkowska-Jakubas B,Wrzesien-Kus A,Bieniaszewska M,Duda D,Szydlo R,Halaburda K,Szczepinski A,Lange A,Hellman A,Robak T,Skotnicki A

    更新日期:2007-11-01 00:00:00

  • GI complications in pediatric patients post-BMT.

    abstract::This retrospective study comprehensively examined hepatic and gastrointestinal complications post-bone marrow transplant (BMT) in a heterogeneous group of 132 pediatric patients that underwent 142 transplants. Hyperbilirubinemia occurred in 28% of this population with clinically evident jaundice in 16%. Acute graft-ve...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705004

    authors: Barker CC,Anderson RA,Sauve RS,Butzner JD

    更新日期:2005-07-01 00:00:00

  • Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

    abstract::The natural history of multiple myeloma (MM) was revolutionized by the introduction of haematopoietic stem cell transplantation to the treatment armamentarium of this disease. Defined subgroups of MM patients (such as the elderly or dialysis-dependent) have required an individualized approach in order to minimize the ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705395

    authors: Bahlis NJ,Lazarus HM

    更新日期:2006-07-01 00:00:00

  • Successful second allogeneic peripheral blood stem cell transplantation and donor lymphocyte infusion in patients with relapsed acute leukemia using the same donors as for the initial allogeneic bone marrow transplantation.

    abstract::We report the successful treatment of two acute lympho- blastic leukemia (ALL) patients who relapsed following allogeneic bone marrow transplantation (allo-BMT) with allogeneic peripheral blood sem cell transplantation(allo-PBSCT) and donor lymphocyte infusion (DLI) from the same HLA-identical related donors as those ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704059

    authors: Ishikawa J,Maeda T,Kashiwagi H,Yoshida H,Takahashi I,Kawamoto SI,Yamada M,Kato H,Nishiura T,Tomiyama Y,Matsuzawa Y

    更新日期:2003-06-01 00:00:00

  • Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

    abstract::Forty-two patients allografted for multiple myeloma after not having attained at least a partial remission (n = 19) or after having experienced disease progression (n = 23) following one autograft were compared with 42 pair-matched controls who underwent salvage autotransplantation under identical conditions. Autograf...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701208

    authors: Mehta J,Tricot G,Jagannath S,Ayers D,Singhal S,Siegel D,Desikan K,Munshi N,Fassas A,Mattox S,Vesole D,Crowley J,Barlogie B

    更新日期:1998-05-01 00:00:00

  • Growth in homozygous beta-thalassemia after bone marrow transplantation.

    abstract::In 8 homozygous beta-thalassemic patients, aged between 1.9 and 18 years, that received bone marrow transplantation (BMT), a longtidinal study of growth before and after BMT and relative Height Standard Deviation Score (SDS), has been performed. In all patients, also after BMT, a progressive growth retardation has bee...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ponte G,Ferrara M,Esposito L

    更新日期:1991-01-01 00:00:00

  • Conditioning with cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia.

    abstract::Graft rejection has been a problem after bone marrow transplantation for patients with severe aplastic anemia (SAA). Ten children with SAA were conditioned for bone marrow transplantation from HLA-identical siblings, using cyclophosphamide (CY, 50 mg/kg) plus antithymocyte globulin (ATG, 15 mg/kg) for 4 successive day...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700795

    authors: Azuma E,Kojima S,Kato K,Matsuyama T,Yamada Y,Kondo N,Sawada H,Hanada M,Shibata T,Tabata N,Watanabe M,Shimono Y,Deguchi T,Umemoto M,Higashikawa M,Kawasaki H,Komada Y,Sakurai M

    更新日期:1997-06-01 00:00:00

  • Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells.

    abstract::Six patients treated for relapsed chronic myeloid leukaemia after allogeneic bone marrow transplantation with donor buffy coat transfusions were investigated. In the 5 patients who achieved molecular remission high frequencies of host-reactive interleukin 2-secreting T helper cell precursors (Th-p) were detectable by ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bunjes D,Theobald M,Hertenstein B,Wiesneth M,Novotny J,Arnold R,Heimpel H

    更新日期:1995-05-01 00:00:00

  • Gene therapy for hematopoietic and immune disorders.

    abstract::Gene therapy is a novel approach under investigation for the treatment of genetic diseases, cancer and AIDS. Hematopoietic stem cells would be the target cell for correction of hemoglobinopathies, immune deficiencies and lysosomal storage diseases. Retroviral vectors derived from murine leukemia viruses have been used...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Kohn DB

    更新日期:1996-12-01 00:00:00

  • Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.

    abstract::Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2011.33

    authors: Milone G,Poidomani M,Leotta S,Avola G,Camuglia MG,Privitera A,Consoli C,Mercurio S,Romeo MA,Di Marco A,Di Mercurio S,Spadaro A,Palumbo GA,Tedeschi P

    更新日期:2012-01-01 00:00:00

  • Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas.

    abstract::We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) aph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-017-0047-7

    authors: Kardduss-Urueta A,Gale RP,Gutierrez-Aguirre CH,Herrera-Rojas MA,Murrieta-Álvarez I,Perez-Fontalvo R,Ruiz-Delgado GJ,Ruiz-Rojas G,Jaimovich G,Feldman L,Labastida-Mercado N,Endara A,Castro M,Galindo-Becerra S,Cardona-Molina MA

    更新日期:2018-04-01 00:00:00

  • Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD).

    abstract::A double-blind, placebo-controlled study was conducted to evaluate the effect of orally administered pilocarpine on unstimulated whole-saliva flow and composition in 28 patients with chronic graft-versus-host disease (cGVHD). Thirteen patients were treated with pilocarpine of 20 mg/day orally for 7 days, and 15 patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705621

    authors: Agha-Hosseini F,Mirzaii-Dizgah I,Ghavamzadeh L,Ghavamzadeh A,Tohidast-Acrad Z

    更新日期:2007-04-01 00:00:00

  • Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.

    abstract::The Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI) is used to counsel patients regarding the risk of transplantation and selection of conditioning regimens. Pulmonary disease, most frequently demonstrated by a decreased diffusion capacity of carbon monoxide (DLCO), is the most prevalent comorbi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.31

    authors: Coffey DG,Pollyea DA,Myint H,Smith C,Gutman JA

    更新日期:2013-09-01 00:00:00

  • Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.

    abstract::Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702378

    authors: Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

    更新日期:2000-05-01 00:00:00

  • Allogeneic transplant can abrogate the risk of relapse in the patients of first remission acute myeloid leukemia with detectable measurable residual disease by next-generation sequencing.

    abstract::In patients with acute myeloid leukemia (AML) consolidation treatment options are between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy, based on disease risk at the time of initial presentation and age. Measurable residual disease (MRD) following induction chemotherapy could be incorporate...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01165-x

    authors: Ahn JS,Kim T,Jung SH,Ahn SY,Jung SY,Song GY,Kim M,Yang DH,Lee JJ,Choi S,Lee JY,Park SK,Moon JH,Lee HY,Kim KH,Cai Y,Yi SY,Novitzky-Basso I,Zhang Z,Kim HJ,Kim DDH

    更新日期:2020-12-05 00:00:00

  • Are backup BM harvests worthwhile in unrelated donor allogeneic transplants?

    abstract::The Cleveland Clinic blood and marrow transplant program has routinely performed 'backup' autologous harvests in unrelated recipients with hematological malignancies in remission, lymphoma without marrow involvement and CML in chronic phase. We reviewed all adult or cord unrelated donor (URD) transplants performed fro...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2009.95

    authors: Stotler C,Bolwell B,Sobecks R,Dean R,Serafino S,Rybicki L,Andresen S,Pohlman B,Kalaycio M,Copelan E

    更新日期:2010-01-01 00:00:00

  • Hexaminolevulinate-mediated photodynamic purging of marrow grafts with murine breast carcinoma.

    abstract::Photodynamic therapy (PDT) with porphyrin precursors is an established therapy for certain tumors. This study aimed to explore the use of hexaminolevulinate (HAL), a porphyrin precursor, for photodynamic purging of BM grafts contaminated with cells of the 4T1 breast carcinoma cell line. The optimal PDT dose was not ef...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.277

    authors: Čunderlíková B,Vasovič V,Sieber F,Furre T,Borgen E,Nesland JM,Peng Q

    更新日期:2011-08-01 00:00:00

  • Successful vidarabine therapy for adenovirus type 11-associated acute hemorrhagic cystitis after allogeneic bone marrow transplantation.

    abstract::A 36-year-old man underwent an allogeneic BMT for acute lymphoblastic leukemia. Eighteen days later the patient developed sudden onset of painful, gross hematuria due to adenovirus type 11 infection that did not respond to conservative therapy. There was an increase in serum creatinine levels and delayed recovery of t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Kitabayashi A,Hirokawa M,Kuroki J,Nishinari T,Niitsu H,Miura AB

    更新日期:1994-11-01 00:00:00

  • Adenovirus infections following haematopoietic cell transplantation: is there a role for adoptive immunotherapy?

    abstract::Adenovirus has been recognised as an important pathogen in BMT recipients, especially in patients with GVHD and those receiving T cell-depleted allografts. We report adenovirus infections from an ongoing surveillance study in four patients after a non-myeloablative transplant and their improved outcome following withd...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702508

    authors: Chakrabarti S,Collingham KE,Fegan CD,Pillay D,Milligan DW

    更新日期:2000-08-01 00:00:00

  • Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

    abstract::The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2010.249

    authors: Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

    更新日期:2011-08-01 00:00:00